卵巢癌是妇科恶性肿瘤中死亡率最高的疾病，寻找有效的治疗方法来提高其生存率及生活质量是目前急需解决的问题。细胞毒性T淋巴细胞（CTL）具有细胞毒活性高、抗肿瘤谱广的特点，有望成为针对卵巢癌患者进行个体化治疗的新方法。但是目前研究中的CTL细胞存在的抗原特异性差，缺乏有效的抗原递呈作用，细胞数量少等问题。项目组利用已经成熟掌握的蛋白大规模发酵技术、制备HER2特异性CTL细胞的培养技术、细胞质量评估技术以及鉴定技术，将卵巢癌组织中高表达的人源HER2抗原胞外区（ECD）蛋白在80L发酵罐中进行发酵与纯化，提高产量、降低成本。将足量的HER2抗原与免疫佐剂CPG-ODN结合，同时联合人参皂甙Rg1诱导建立从20ml血液中就获得1×1010高活性的、单一克隆的HER2-CTL培养体系，在此基础之上研究其抗卵巢癌作用。弥补了目前相关研究中存在的不足，为卵巢癌患者进行个体化的细胞免疫治疗提供实验基础。

Ovarian cancer is the highest mortality gynecological malignancies, looking for more effective treatment methods to improve the survival rate and quality of life of patients with ovarian cancer is urgently needed to resolve the problem. Cytotoxic T lymphocytes (CTL) having a high cytotoxic activity, the characteristics of the broad spectrum of anti-tumor, and is expected to become a new method of individualized immunotherapy for patients with ovarian cancer. But now the presence of antigen-specific CTL cell research and use, lack of effective antigen presentation, a small number of cells and other issues. Project team used genetic engineering techniques, large-scale fermentation technology, purification techniques, source HER2 antigen highly expressed in ovarian cancer tissue outer region of the cell (ECD) gene was amplified expression, while further fermentation in 80L fermenter purification, increase productivity, and reduce costs. And sufficient quantities of the HER2 antigen and immune adjuvant CPG-ODN combined, at the same time joint the ginsenosides Rg1 induced by high activity and stability of HER2-CTL culture system built from 20ml blood. The project team has been mastered preparation HER2-specific CTL cell culture techniques, cell quality assessment technology, and identification techniques to study the growth inhibition of ovarian cancer on this basis, the role of anti-adhesion, invasion, to make up for the current research the field in the presence of insufficient specificity HER2-CTL individualized immunotherapy for patients with ovarian cancer to provide experimental basis.